---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002673"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:24:55.279966+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Beam dosed first SCD patient, submitted CTA for AATD, cash $1.2B into 2027

## Summary
- First patient dosed in BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease; initial data expected H2 2024.
- CTA submitted for BEAM-302 in alpha-1 antitrypsin deficiency; trial initiation planned H1 2024.
- IND for BEAM-301 in glycogen storage disease 1a on track for H1 2024.
- Estimated cash, cash equivalents and marketable securities of $1.2B as of Dec 31, 2023, funding operations into 2027.
- BEAM-201 CAR-T trial enrollment ongoing; initial clinical dataset expected H2 2024.

## SEC filing metadata
- accession: 0000950170-24-002673
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017024002673/0000950170-24-002673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017024002673/beam-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002673
- JSON: https://secwatch.observer/filing/0000950170-24-002673.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002673.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.